28th Sep 2021 07:00
28 September 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Purchase and Transfer of Shares and PDMR Shareholdings
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company announces that on 27 September 2021, Deborah Davis, the Chair of Diaceutics, purchased 17,800 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.11 pence per Ordinary Share.
In addition, Philip White transferred 150,000 Ordinary Shares to his father, Philip Michael White.
As a result of the purchase, Deborah's shareholding is 44,800 Ordinary Shares, representing approximately 0.05 % of the Company's issued share capital and as a result of Philip's transfer, the beneficial holding of Philip White will be 1,606,389 Ordinary Shares, representing 1.91 % of the Company's issued share capital.
Enquiries:
Diaceutics PLC |
|
Philip White, Chief Financial Officer | Via Alma PR |
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison |
|
Stewart Wallace |
|
Nick Adams |
|
|
|
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | |
Robyn Fisher |
|
Kieran Breheny |
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Deborah Davis | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chair | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Purchase | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
1.11 | 17,800 | ||||||
d. | Date of the transaction | 27 September 2021 | |||||
e. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Philip White | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Financial Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Transfer of ordinary shares for nil consideration to PDMR's father | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
Nil | 150,000 | ||||||
| |||||||
e. | Date of the transaction | 27 September 2021 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Related Shares:
Diaceutics